The study demonstrated that the low dose combination antiviral therapy IMC-2 treated patient cohort (valacyclovir 750 mg + celecoxib dosed 200 mg twice daily ... the primary endpoint agreed with the ...
Dogwood Therapeutics, Inc. (DWTX), a development-stage biotechnology company, announced on Monday the top-line data from the recently ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback